This appraisal has been split into the adult and paediatric populations. ID6486 will continue as the evaluation of budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over. The evaluation of budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years will progress under ID6761. The evaluation of ID6486 is expected to begin in early January 2027, with submissions expected in early March 2027.